These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14630265)

  • 21. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF; Nelson JW; Alkaissi AK; Das S; Clough RW; Broadwater G; Anscher MS; Chino JP; Oleson JR
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):139-46. PubMed ID: 19836161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gleason 7 prostate cancer treated with low-dose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure.
    Stock RG; Berkowitz J; Blacksburg SR; Stone NN
    BJU Int; 2012 Nov; 110(9):1257-61. PubMed ID: 22571680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose-response study for I-125 prostate implants.
    Stock RG; Stone NN; Tabert A; Iannuzzi C; DeWyngaert JK
    Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):101-8. PubMed ID: 9588923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
    Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
    Brachman DG; Thomas T; Hilbe J; Beyer DC
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes.
    Stone NN; Skouteris VM; Rosenstein BS; Stock RG
    Brachytherapy; 2020; 19(5):567-573. PubMed ID: 32763013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation.
    Orio P; Wallner K; Merrick G; Herstein A; Mitsuyama P; Thornton K; Butler W; Sutlief S
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):342-6. PubMed ID: 17236959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma.
    Ellis RJ; Vertocnik A; Kim E; Zhou H; Young B; Sodee B; Fu P; Beddar S; Colussi V; Spirnak JP; Dinchman KH; Resnick M; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):362-70. PubMed ID: 12957246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. There is a wide range of predictive dosimetric factors for I-125 and pd-103 prostate brachytherapy.
    Herstein A; Wallner K; Merrick G; Orio P; Thornton K; Butler W; Sutlief S
    Am J Clin Oncol; 2008 Feb; 31(1):6-10. PubMed ID: 18376221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
    Pollack A; Zagars GK; Antolak JA; Kuban DA; Rosen II
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):677-85. PubMed ID: 12377318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma.
    Dattoli M; Wallner K; True L; Sorace R; Koval J; Cash J; Acosta R; Biswas M; Binder M; Sullivan B; Lastarria E; Kirwan N; Stein D
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):853-6. PubMed ID: 10571189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical correlates of high intraprostatic brachytherapy dose volumes.
    Jones S; Wallner K; Merrick G; Corriveau J; Sutlief S; True L; Butler W
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):328-33. PubMed ID: 12023136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.